Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 March;43(1) > The Quarterly Journal of Nuclear Medicine 1999 March;43(1):100-12

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  IMAGING INFECTION


The Quarterly Journal of Nuclear Medicine 1999 March;43(1):100-12

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Imaging of auto­im­mune dis­eas­es

Procaccini E., Chianelli M.*, Pantano P.**, Signore A.

From the NuMED Group Servizio Speciale di Medicina Nucleare II Clinica Medica
** Clinica Neurologica University of Rome “La Sapienza”, Rome, Italy
* Servizio di Medicina Nucleare Dipartimento di Diagnostica Ospedale Regina Apostolorum, Albano, Rome, Italy


FULL TEXT  


Autoimmune dis­eas­es rep­re­sent a het­er­o­ge­ne­ous ­group of pathol­o­gies ­with a ­wide ­range of immu­no­log­i­cal chang­es and clin­i­cal pres­en­ta­tions. The clin­i­cal ­onset of the dis­ease com­mon­ly ­occurs ­when ­signs and sym­ptoms of tar­get tis­sue hypo­func­tion ­appear; com­pli­ca­tions can ­also be ­present. The aim of an imag­ing diag­nos­tic tech­nique in ­this con­text is to cor­rect­ly eval­u­ate the dis­ease ­extent and sever­ity for appro­pri­ate treat­ment and to fol­low up the effi­ca­cy of ther­a­py. In addi­tion, iden­tifi­ca­tion of sub­jects at ­risk and the pre­clin­i­cal diag­no­sis may ­allow dis­ease pre­ven­tion. Ultrasound (US), con­ven­tion­al radiol­o­gy and com­put­ed tomog­ra­phy (CT) are ­often ­used for a ­detailed mor­pho­log­i­cal ­study of tis­sues ­involved; mag­net­ic res­o­nance (MRI) may ­also dem­on­strate bio­chem­i­cal and struc­tu­ral tis­sue chang­es. Nuclear med­i­cine tech­niques are ­known for ­their sen­si­tiv­ity and spec­i­fic­ity and in ­recent ­years an expand­ing ­field is rep­re­sent­ed by the devel­op­ment of radio­lab­elled recep­tor ­ligands. New radio­phar­ma­ceu­ti­cals ­able to ­bind in ­vivo to spe­cif­ic recep­tors ­have ­been intro­duced allow­ing the non inva­sive detec­tion of chang­es in affect­ed tis­sues. The rel­e­vant cri­te­ria to ­choose dif­fer­ent diag­nos­tic approach­es in sev­er­al auto­im­mune dis­eas­es are dis­cussed in ­this ­review. In par­tic­u­lar the ­role and con­tri­bu­tion of nucle­ar med­i­cine for the ­study of auto­im­mune dis­eas­es have ­been ­described.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail